Michel Chonchol
Concepts (708)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 87 | 2025 | 661 | 11.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 36 | 2026 | 235 | 9.800 |
Why?
| | Kidney Failure, Chronic | 57 | 2026 | 599 | 7.100 |
Why?
| | Glomerular Filtration Rate | 92 | 2026 | 765 | 6.040 |
Why?
| | Renal Dialysis | 35 | 2026 | 466 | 5.790 |
Why?
| | Kidney | 51 | 2026 | 1494 | 5.480 |
Why?
| | Kidney Diseases | 33 | 2025 | 424 | 4.810 |
Why?
| | Fibroblast Growth Factors | 25 | 2020 | 188 | 4.660 |
Why?
| | Cardiovascular Diseases | 57 | 2023 | 2183 | 4.020 |
Why?
| | Vitamin D | 31 | 2022 | 403 | 3.670 |
Why?
| | Hypertension | 37 | 2022 | 1269 | 2.680 |
Why?
| | Vitamin D Deficiency | 13 | 2024 | 190 | 2.510 |
Why?
| | Vascular Stiffness | 20 | 2025 | 486 | 2.370 |
Why?
| | Endothelium, Vascular | 18 | 2025 | 955 | 2.260 |
Why?
| | Phosphates | 12 | 2024 | 177 | 2.260 |
Why?
| | Disease Progression | 44 | 2026 | 2857 | 2.230 |
Why?
| | Kidney Calculi | 5 | 2024 | 44 | 2.130 |
Why?
| | Blood Pressure | 35 | 2023 | 1778 | 2.070 |
Why?
| | Nutrition Surveys | 15 | 2024 | 279 | 2.040 |
Why?
| | Phosphorus | 13 | 2017 | 90 | 1.930 |
Why?
| | Aged | 176 | 2026 | 26096 | 1.850 |
Why?
| | Middle Aged | 173 | 2026 | 36126 | 1.830 |
Why?
| | Blood Vessels | 4 | 2024 | 167 | 1.810 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2025 | 442 | 1.800 |
Why?
| | Oxidative Stress | 21 | 2026 | 1351 | 1.780 |
Why?
| | Male | 237 | 2026 | 72664 | 1.750 |
Why?
| | Uric Acid | 12 | 2021 | 167 | 1.750 |
Why?
| | Nephrology | 5 | 2022 | 60 | 1.730 |
Why?
| | Humans | 312 | 2026 | 145140 | 1.700 |
Why?
| | Female | 236 | 2026 | 78636 | 1.680 |
Why?
| | Cholecalciferol | 6 | 2024 | 61 | 1.650 |
Why?
| | Creatinine | 25 | 2021 | 513 | 1.610 |
Why?
| | Risk Factors | 91 | 2025 | 10857 | 1.570 |
Why?
| | Sodium, Dietary | 4 | 2024 | 42 | 1.540 |
Why?
| | Inflammation | 21 | 2025 | 2876 | 1.490 |
Why?
| | Potassium, Dietary | 3 | 2024 | 12 | 1.480 |
Why?
| | Chronic Kidney Disease-Mineral and Bone Disorder | 4 | 2020 | 14 | 1.450 |
Why?
| | Double-Blind Method | 31 | 2025 | 2057 | 1.450 |
Why?
| | Parathyroid Hormone | 18 | 2020 | 114 | 1.430 |
Why?
| | Vascular Calcification | 8 | 2022 | 110 | 1.350 |
Why?
| | Dietary Supplements | 10 | 2021 | 582 | 1.290 |
Why?
| | Biomarkers | 45 | 2025 | 4282 | 1.260 |
Why?
| | Brachial Artery | 12 | 2025 | 208 | 1.250 |
Why?
| | Lanthanum | 4 | 2024 | 13 | 1.200 |
Why?
| | Pravastatin | 3 | 2025 | 45 | 1.150 |
Why?
| | Adult | 86 | 2026 | 40665 | 1.140 |
Why?
| | Calcium | 13 | 2020 | 1189 | 1.140 |
Why?
| | Fatty Liver | 10 | 2013 | 253 | 1.070 |
Why?
| | Antihypertensive Agents | 14 | 2021 | 517 | 1.070 |
Why?
| | Coronary Disease | 7 | 2010 | 381 | 1.020 |
Why?
| | Metabolic Syndrome | 7 | 2025 | 360 | 1.020 |
Why?
| | Naphthalenes | 4 | 2015 | 54 | 1.020 |
Why?
| | Bacterial Infections | 3 | 2016 | 246 | 1.010 |
Why?
| | Pulse Wave Analysis | 12 | 2025 | 267 | 1.010 |
Why?
| | Cross-Sectional Studies | 42 | 2026 | 5886 | 1.000 |
Why?
| | Vasodilation | 8 | 2025 | 521 | 0.990 |
Why?
| | Adrenergic beta-Antagonists | 7 | 2011 | 252 | 0.980 |
Why?
| | Prevalence | 27 | 2024 | 2855 | 0.970 |
Why?
| | Prospective Studies | 42 | 2025 | 8035 | 0.960 |
Why?
| | Vascular Diseases | 7 | 2021 | 252 | 0.940 |
Why?
| | Obesity | 6 | 2026 | 3097 | 0.940 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 747 | 0.920 |
Why?
| | Community Health Workers | 2 | 2026 | 88 | 0.900 |
Why?
| | Hyperparathyroidism, Secondary | 4 | 2009 | 12 | 0.880 |
Why?
| | Renal Insufficiency | 7 | 2025 | 172 | 0.860 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 465 | 0.850 |
Why?
| | Minerals | 6 | 2022 | 48 | 0.830 |
Why?
| | Cognition | 6 | 2023 | 1262 | 0.820 |
Why?
| | Acute Kidney Injury | 10 | 2022 | 872 | 0.810 |
Why?
| | Curcumin | 2 | 2021 | 28 | 0.810 |
Why?
| | Cohort Studies | 32 | 2024 | 5988 | 0.800 |
Why?
| | Intra-Abdominal Fat | 1 | 2024 | 101 | 0.770 |
Why?
| | Anemia | 5 | 2020 | 190 | 0.750 |
Why?
| | Proportional Hazards Models | 30 | 2019 | 1325 | 0.740 |
Why?
| | Follow-Up Studies | 37 | 2020 | 5411 | 0.730 |
Why?
| | Albuminuria | 13 | 2022 | 189 | 0.730 |
Why?
| | Overweight | 3 | 2026 | 609 | 0.730 |
Why?
| | Pregnancy Complications | 3 | 2018 | 600 | 0.720 |
Why?
| | Aged, 80 and over | 43 | 2023 | 8318 | 0.720 |
Why?
| | Incidence | 28 | 2021 | 2915 | 0.710 |
Why?
| | Non-alcoholic Fatty Liver Disease | 9 | 2016 | 265 | 0.710 |
Why?
| | Atherosclerosis | 8 | 2021 | 409 | 0.710 |
Why?
| | Weight Gain | 1 | 2026 | 561 | 0.700 |
Why?
| | Vascular Surgical Procedures | 13 | 2011 | 343 | 0.690 |
Why?
| | Metformin | 2 | 2024 | 327 | 0.680 |
Why?
| | Kidney Tubules | 5 | 2024 | 118 | 0.670 |
Why?
| | Kidney Function Tests | 12 | 2017 | 156 | 0.660 |
Why?
| | Calcimimetic Agents | 1 | 2020 | 3 | 0.650 |
Why?
| | Kidney Transplantation | 3 | 2022 | 710 | 0.650 |
Why?
| | Vitamins | 3 | 2022 | 182 | 0.650 |
Why?
| | Hyponatremia | 2 | 2018 | 43 | 0.650 |
Why?
| | Patient Navigation | 4 | 2026 | 126 | 0.640 |
Why?
| | Calcitriol | 2 | 2018 | 57 | 0.640 |
Why?
| | Cystatin C | 7 | 2013 | 66 | 0.640 |
Why?
| | Sodium | 2 | 2019 | 198 | 0.630 |
Why?
| | Diabetic Nephropathies | 6 | 2025 | 319 | 0.630 |
Why?
| | Systole | 8 | 2020 | 181 | 0.630 |
Why?
| | Bicarbonates | 5 | 2023 | 45 | 0.620 |
Why?
| | Renal Artery Obstruction | 3 | 2014 | 30 | 0.620 |
Why?
| | Treatment Outcome | 39 | 2025 | 11741 | 0.620 |
Why?
| | Renin-Angiotensin System | 3 | 2017 | 80 | 0.620 |
Why?
| | Bone Diseases | 1 | 2020 | 61 | 0.620 |
Why?
| | Time Factors | 30 | 2022 | 7107 | 0.610 |
Why?
| | Odds Ratio | 13 | 2024 | 1082 | 0.610 |
Why?
| | Interleukin-1 | 3 | 2019 | 961 | 0.600 |
Why?
| | Sodium Bicarbonate | 2 | 2023 | 47 | 0.600 |
Why?
| | Prognosis | 27 | 2021 | 4310 | 0.580 |
Why?
| | United States | 36 | 2026 | 16065 | 0.570 |
Why?
| | Spironolactone | 1 | 2019 | 40 | 0.570 |
Why?
| | Chronic Disease | 19 | 2017 | 1806 | 0.560 |
Why?
| | Cause of Death | 6 | 2018 | 470 | 0.560 |
Why?
| | Simvastatin | 3 | 2014 | 59 | 0.550 |
Why?
| | Acidosis | 2 | 2018 | 105 | 0.550 |
Why?
| | Heart Diseases | 4 | 2015 | 341 | 0.550 |
Why?
| | Young Adult | 24 | 2025 | 14176 | 0.550 |
Why?
| | Calcium, Dietary | 2 | 2009 | 52 | 0.550 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 69 | 0.550 |
Why?
| | Hypertrophy, Left Ventricular | 4 | 2017 | 123 | 0.540 |
Why?
| | Hemoglobins | 4 | 2009 | 386 | 0.540 |
Why?
| | Caloric Restriction | 4 | 2024 | 129 | 0.530 |
Why?
| | Recombinant Fusion Proteins | 2 | 2017 | 666 | 0.530 |
Why?
| | Arterial Pressure | 1 | 2018 | 134 | 0.530 |
Why?
| | Accidental Falls | 1 | 2020 | 225 | 0.520 |
Why?
| | Endothelial Cells | 5 | 2023 | 873 | 0.520 |
Why?
| | Death, Sudden, Cardiac | 5 | 2015 | 231 | 0.510 |
Why?
| | Carotid Artery Diseases | 3 | 2021 | 70 | 0.510 |
Why?
| | Calcinosis | 6 | 2017 | 234 | 0.510 |
Why?
| | Frailty | 1 | 2020 | 203 | 0.510 |
Why?
| | Multivariate Analysis | 14 | 2017 | 1546 | 0.510 |
Why?
| | Diet | 4 | 2025 | 1277 | 0.510 |
Why?
| | Logistic Models | 12 | 2024 | 2133 | 0.500 |
Why?
| | Interleukin-6 | 2 | 2020 | 775 | 0.500 |
Why?
| | Bone Density | 5 | 2017 | 484 | 0.490 |
Why?
| | Renal Circulation | 3 | 2026 | 75 | 0.490 |
Why?
| | Calciphylaxis | 1 | 2016 | 2 | 0.490 |
Why?
| | Longitudinal Studies | 17 | 2020 | 2949 | 0.480 |
Why?
| | Uremia | 1 | 2016 | 15 | 0.480 |
Why?
| | Conservative Treatment | 1 | 2017 | 44 | 0.480 |
Why?
| | Sodium Chloride | 1 | 2017 | 138 | 0.470 |
Why?
| | Dementia | 4 | 2025 | 325 | 0.470 |
Why?
| | Pregnancy Outcome | 3 | 2018 | 500 | 0.460 |
Why?
| | Primary Prevention | 3 | 2018 | 218 | 0.460 |
Why?
| | Randomized Controlled Trials as Topic | 12 | 2023 | 1742 | 0.460 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 229 | 0.460 |
Why?
| | Hyperuricemia | 5 | 2018 | 47 | 0.460 |
Why?
| | Diet, Sodium-Restricted | 4 | 2020 | 38 | 0.460 |
Why?
| | Fluid Therapy | 1 | 2017 | 154 | 0.450 |
Why?
| | Peripheral Vascular Diseases | 7 | 2012 | 104 | 0.440 |
Why?
| | Ventricular Dysfunction, Left | 6 | 2014 | 393 | 0.440 |
Why?
| | Insulin Resistance | 7 | 2025 | 1244 | 0.440 |
Why?
| | Myocardial Infarction | 10 | 2017 | 1210 | 0.440 |
Why?
| | Diabetes Complications | 6 | 2018 | 224 | 0.430 |
Why?
| | Comorbidity | 13 | 2018 | 1657 | 0.430 |
Why?
| | Diabetes Mellitus, Type 2 | 10 | 2012 | 2578 | 0.430 |
Why?
| | Liver | 2 | 2016 | 1893 | 0.430 |
Why?
| | Undocumented Immigrants | 3 | 2023 | 63 | 0.430 |
Why?
| | Body Mass Index | 11 | 2026 | 2437 | 0.420 |
Why?
| | Retrospective Studies | 33 | 2024 | 17247 | 0.420 |
Why?
| | Peripheral Arterial Disease | 7 | 2021 | 506 | 0.420 |
Why?
| | Fructose | 2 | 2016 | 132 | 0.410 |
Why?
| | Cardiovascular Agents | 4 | 2013 | 166 | 0.410 |
Why?
| | Risk Assessment | 24 | 2021 | 3740 | 0.410 |
Why?
| | Survival Rate | 14 | 2020 | 2087 | 0.410 |
Why?
| | Hyperphosphatemia | 4 | 2020 | 15 | 0.400 |
Why?
| | Pyrazoles | 2 | 2014 | 517 | 0.400 |
Why?
| | Sodium Nitrite | 3 | 2021 | 39 | 0.390 |
Why?
| | Ankle Brachial Index | 4 | 2014 | 41 | 0.390 |
Why?
| | Pyridines | 2 | 2014 | 608 | 0.390 |
Why?
| | C-Reactive Protein | 8 | 2018 | 422 | 0.380 |
Why?
| | Pneumonia, Bacterial | 1 | 2014 | 113 | 0.380 |
Why?
| | Aging | 6 | 2026 | 1962 | 0.380 |
Why?
| | Disease Management | 2 | 2026 | 651 | 0.380 |
Why?
| | TRPP Cation Channels | 5 | 2022 | 74 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 7 | 2024 | 3892 | 0.370 |
Why?
| | Nephrolithiasis | 1 | 2012 | 10 | 0.370 |
Why?
| | Organ Size | 3 | 2025 | 459 | 0.360 |
Why?
| | Antioxidants | 3 | 2026 | 550 | 0.360 |
Why?
| | Magnesium | 2 | 2014 | 156 | 0.360 |
Why?
| | Chi-Square Distribution | 10 | 2017 | 527 | 0.360 |
Why?
| | Community-Acquired Infections | 1 | 2014 | 177 | 0.360 |
Why?
| | Hemostasis | 2 | 2009 | 98 | 0.360 |
Why?
| | Radius | 1 | 2012 | 51 | 0.360 |
Why?
| | Carotid Arteries | 4 | 2018 | 208 | 0.350 |
Why?
| | Case-Control Studies | 12 | 2025 | 3616 | 0.350 |
Why?
| | Heart Ventricles | 2 | 2013 | 754 | 0.340 |
Why?
| | Hypothyroidism | 2 | 2009 | 67 | 0.340 |
Why?
| | Health Status | 3 | 2015 | 832 | 0.330 |
Why?
| | Mitochondria | 3 | 2026 | 992 | 0.330 |
Why?
| | Health Surveys | 3 | 2014 | 517 | 0.330 |
Why?
| | Independent Living | 5 | 2018 | 116 | 0.330 |
Why?
| | Kaplan-Meier Estimate | 14 | 2018 | 968 | 0.330 |
Why?
| | Coronary Artery Bypass | 3 | 2014 | 268 | 0.330 |
Why?
| | Colorado | 11 | 2026 | 4538 | 0.330 |
Why?
| | Physical Fitness | 1 | 2012 | 207 | 0.320 |
Why?
| | Resistance Training | 2 | 2023 | 186 | 0.320 |
Why?
| | NAD | 2 | 2023 | 79 | 0.320 |
Why?
| | Blood Coagulation Disorders | 2 | 2010 | 198 | 0.320 |
Why?
| | Internship and Residency | 2 | 2020 | 1264 | 0.320 |
Why?
| | Hip Fractures | 3 | 2017 | 87 | 0.310 |
Why?
| | Hypercapnia | 3 | 2025 | 53 | 0.310 |
Why?
| | Homeostasis | 5 | 2018 | 639 | 0.310 |
Why?
| | Ischemia | 3 | 2011 | 422 | 0.310 |
Why?
| | Lovastatin | 1 | 2009 | 37 | 0.300 |
Why?
| | Dyslipidemias | 2 | 2013 | 184 | 0.300 |
Why?
| | Polycystic Kidney Diseases | 2 | 2023 | 71 | 0.300 |
Why?
| | Zinc | 1 | 2012 | 301 | 0.300 |
Why?
| | gamma-Glutamyltransferase | 1 | 2009 | 42 | 0.300 |
Why?
| | Mortality | 5 | 2020 | 378 | 0.300 |
Why?
| | Endocrine System Diseases | 1 | 2009 | 35 | 0.300 |
Why?
| | Blood Coagulation | 3 | 2011 | 274 | 0.300 |
Why?
| | Weight Loss | 1 | 2015 | 845 | 0.290 |
Why?
| | Hospitals, Veterans | 2 | 2008 | 258 | 0.290 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 4 | 2024 | 43 | 0.290 |
Why?
| | Lipocalin-2 | 4 | 2024 | 80 | 0.280 |
Why?
| | Fibrinolysis | 2 | 2011 | 164 | 0.280 |
Why?
| | Uromodulin | 5 | 2022 | 22 | 0.280 |
Why?
| | Hospitalization | 3 | 2016 | 2458 | 0.280 |
Why?
| | Bilirubin | 1 | 2009 | 99 | 0.280 |
Why?
| | Regional Blood Flow | 5 | 2017 | 514 | 0.280 |
Why?
| | Bone and Bones | 2 | 2012 | 317 | 0.270 |
Why?
| | Phosphorus Metabolism Disorders | 1 | 2007 | 1 | 0.270 |
Why?
| | Severity of Illness Index | 12 | 2020 | 2928 | 0.270 |
Why?
| | Coronary Angiography | 3 | 2012 | 328 | 0.260 |
Why?
| | Sepsis | 1 | 2014 | 662 | 0.260 |
Why?
| | Cross-Over Studies | 6 | 2026 | 608 | 0.260 |
Why?
| | Magnetic Resonance Angiography | 2 | 2025 | 250 | 0.260 |
Why?
| | Aorta | 3 | 2021 | 439 | 0.250 |
Why?
| | Ultrasonography | 6 | 2013 | 784 | 0.250 |
Why?
| | Metabolomics | 4 | 2022 | 730 | 0.240 |
Why?
| | Adolescent | 14 | 2023 | 22479 | 0.240 |
Why?
| | Aortic Aneurysm, Abdominal | 6 | 2011 | 167 | 0.240 |
Why?
| | Angiotensin Receptor Antagonists | 2 | 2018 | 115 | 0.240 |
Why?
| | Brain | 2 | 2018 | 2934 | 0.240 |
Why?
| | Electric Countershock | 1 | 2007 | 126 | 0.230 |
Why?
| | Professional Competence | 1 | 2006 | 91 | 0.230 |
Why?
| | Infant, Low Birth Weight | 2 | 2018 | 156 | 0.230 |
Why?
| | Ubiquinone | 1 | 2026 | 35 | 0.230 |
Why?
| | Infant Mortality | 2 | 2018 | 128 | 0.230 |
Why?
| | Coronary Vessels | 3 | 2022 | 246 | 0.230 |
Why?
| | Thrombosis | 1 | 2009 | 401 | 0.230 |
Why?
| | Anticholesteremic Agents | 1 | 2007 | 155 | 0.220 |
Why?
| | Organophosphorus Compounds | 1 | 2026 | 84 | 0.220 |
Why?
| | Deoxycholic Acid | 3 | 2022 | 14 | 0.220 |
Why?
| | Fasting | 4 | 2023 | 276 | 0.220 |
Why?
| | Respiratory Muscles | 2 | 2023 | 37 | 0.220 |
Why?
| | Nitric Oxide | 5 | 2023 | 892 | 0.220 |
Why?
| | Carotid Artery, Internal | 1 | 2025 | 45 | 0.220 |
Why?
| | Cognition Disorders | 3 | 2017 | 539 | 0.210 |
Why?
| | Blood Pressure Determination | 3 | 2020 | 145 | 0.210 |
Why?
| | Wine | 1 | 2024 | 13 | 0.210 |
Why?
| | Survival Analysis | 6 | 2019 | 1371 | 0.210 |
Why?
| | Mitochondria, Muscle | 1 | 2026 | 120 | 0.210 |
Why?
| | Beer | 1 | 2024 | 13 | 0.210 |
Why?
| | Tryptophan | 2 | 2023 | 182 | 0.210 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 206 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2020 | 992 | 0.210 |
Why?
| | Antidiuretic Hormone Receptor Antagonists | 1 | 2024 | 10 | 0.210 |
Why?
| | Pilot Projects | 5 | 2025 | 1889 | 0.210 |
Why?
| | Inflammasomes | 1 | 2025 | 144 | 0.200 |
Why?
| | Linear Models | 6 | 2017 | 844 | 0.200 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 47 | 0.200 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2014 | 3918 | 0.200 |
Why?
| | Nephrotic Syndrome | 1 | 2003 | 43 | 0.200 |
Why?
| | Animals | 16 | 2026 | 37952 | 0.200 |
Why?
| | Nutritional Status | 2 | 2018 | 353 | 0.200 |
Why?
| | Quality of Life | 4 | 2020 | 3194 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 343 | 0.190 |
Why?
| | Diet, Ketogenic | 1 | 2023 | 39 | 0.190 |
Why?
| | Cerebrovascular Circulation | 3 | 2025 | 289 | 0.190 |
Why?
| | Confidence Intervals | 3 | 2012 | 330 | 0.190 |
Why?
| | Terminology as Topic | 1 | 2025 | 256 | 0.190 |
Why?
| | Drug Therapy, Combination | 6 | 2020 | 1043 | 0.190 |
Why?
| | Human Umbilical Vein Endothelial Cells | 2 | 2021 | 104 | 0.190 |
Why?
| | Metabolome | 3 | 2022 | 387 | 0.190 |
Why?
| | Self-Management | 1 | 2025 | 201 | 0.190 |
Why?
| | Up-Regulation | 5 | 2019 | 846 | 0.180 |
Why?
| | Compassion Fatigue | 1 | 2022 | 30 | 0.180 |
Why?
| | Age Factors | 9 | 2025 | 3338 | 0.180 |
Why?
| | Recovery of Function | 3 | 2017 | 715 | 0.180 |
Why?
| | Troponin T | 3 | 2012 | 63 | 0.180 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2014 | 231 | 0.180 |
Why?
| | Diastole | 3 | 2013 | 146 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2006 | 586 | 0.180 |
Why?
| | Child | 9 | 2023 | 22670 | 0.180 |
Why?
| | Military Personnel | 1 | 2009 | 736 | 0.170 |
Why?
| | Physicians | 2 | 2022 | 954 | 0.170 |
Why?
| | Heart Failure | 8 | 2017 | 2324 | 0.170 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.170 |
Why?
| | Sex Factors | 7 | 2025 | 2099 | 0.170 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.170 |
Why?
| | Exercise Tolerance | 1 | 2023 | 283 | 0.170 |
Why?
| | Niacinamide | 2 | 2020 | 87 | 0.170 |
Why?
| | Atrial Fibrillation | 2 | 2020 | 558 | 0.170 |
Why?
| | Toxins, Biological | 1 | 2020 | 12 | 0.170 |
Why?
| | Propanolamines | 2 | 2011 | 40 | 0.160 |
Why?
| | Education | 2 | 2018 | 104 | 0.160 |
Why?
| | Diabetes Mellitus | 4 | 2020 | 1092 | 0.160 |
Why?
| | Predictive Value of Tests | 11 | 2019 | 2115 | 0.160 |
Why?
| | Parathyroidectomy | 1 | 2020 | 9 | 0.160 |
Why?
| | Culturally Competent Care | 1 | 2021 | 72 | 0.160 |
Why?
| | Osteoporotic Fractures | 2 | 2012 | 62 | 0.160 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2018 | 75 | 0.160 |
Why?
| | Motor Activity | 2 | 2015 | 718 | 0.160 |
Why?
| | Neutrophils | 1 | 2006 | 1123 | 0.160 |
Why?
| | Netherlands | 8 | 2012 | 82 | 0.160 |
Why?
| | Sevelamer | 1 | 2020 | 9 | 0.160 |
Why?
| | Intestinal Absorption | 1 | 2021 | 103 | 0.160 |
Why?
| | Placebos | 2 | 2012 | 193 | 0.160 |
Why?
| | Plaque, Atherosclerotic | 1 | 2021 | 61 | 0.160 |
Why?
| | Stroke | 4 | 2017 | 1270 | 0.160 |
Why?
| | Allopurinol | 2 | 2018 | 70 | 0.160 |
Why?
| | Hypokalemia | 1 | 2020 | 24 | 0.160 |
Why?
| | Propensity Score | 2 | 2019 | 374 | 0.160 |
Why?
| | Attitude of Health Personnel | 2 | 2018 | 1186 | 0.150 |
Why?
| | Tunica Intima | 3 | 2010 | 78 | 0.150 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 1321 | 0.150 |
Why?
| | Communication Barriers | 1 | 2021 | 130 | 0.150 |
Why?
| | Acetates | 1 | 2020 | 78 | 0.150 |
Why?
| | Inflammation Mediators | 2 | 2025 | 506 | 0.150 |
Why?
| | Hyperkalemia | 1 | 2020 | 36 | 0.150 |
Why?
| | Feasibility Studies | 2 | 2021 | 1109 | 0.150 |
Why?
| | Age Distribution | 2 | 2012 | 402 | 0.150 |
Why?
| | Mice | 9 | 2026 | 18303 | 0.150 |
Why?
| | Sex Distribution | 2 | 2012 | 386 | 0.150 |
Why?
| | Preoperative Period | 4 | 2014 | 149 | 0.150 |
Why?
| | Energy Metabolism | 2 | 2024 | 933 | 0.150 |
Why?
| | Adiposity | 1 | 2024 | 532 | 0.150 |
Why?
| | Focus Groups | 2 | 2020 | 569 | 0.140 |
Why?
| | Ambulatory Care Facilities | 1 | 2021 | 269 | 0.140 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 837 | 0.140 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2020 | 155 | 0.140 |
Why?
| | Patient Care Planning | 1 | 2020 | 170 | 0.140 |
Why?
| | Calcification, Physiologic | 1 | 2018 | 29 | 0.140 |
Why?
| | Lipoproteins, HDL | 1 | 2019 | 100 | 0.140 |
Why?
| | Neuroimaging | 2 | 2018 | 292 | 0.140 |
Why?
| | Scandinavian and Nordic Countries | 2 | 2008 | 14 | 0.140 |
Why?
| | Carnitine | 1 | 2018 | 91 | 0.140 |
Why?
| | Potassium | 2 | 2020 | 152 | 0.140 |
Why?
| | Reactive Oxygen Species | 4 | 2023 | 611 | 0.130 |
Why?
| | Information Seeking Behavior | 1 | 2018 | 40 | 0.130 |
Why?
| | Pain | 2 | 2020 | 781 | 0.130 |
Why?
| | Electrocardiography | 5 | 2020 | 664 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1579 | 0.130 |
Why?
| | Cholesterol, HDL | 4 | 2013 | 201 | 0.130 |
Why?
| | Healthy Lifestyle | 1 | 2018 | 37 | 0.130 |
Why?
| | Infant, Newborn | 4 | 2018 | 6435 | 0.130 |
Why?
| | Bone Diseases, Metabolic | 1 | 2018 | 58 | 0.130 |
Why?
| | Healthy Aging | 1 | 2018 | 44 | 0.130 |
Why?
| | Adaptive Immunity | 1 | 2018 | 167 | 0.130 |
Why?
| | Emergency Treatment | 1 | 2018 | 123 | 0.130 |
Why?
| | Alcohol Drinking | 1 | 2024 | 836 | 0.130 |
Why?
| | Fellowships and Scholarships | 2 | 2020 | 354 | 0.130 |
Why?
| | Hemodialysis Solutions | 1 | 2017 | 3 | 0.130 |
Why?
| | Femoral Artery | 1 | 2018 | 190 | 0.130 |
Why?
| | Death | 1 | 2018 | 131 | 0.130 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 2 | 2013 | 18 | 0.120 |
Why?
| | Vasopressins | 1 | 2017 | 61 | 0.120 |
Why?
| | Peer Group | 1 | 2019 | 252 | 0.120 |
Why?
| | Living Donors | 1 | 2018 | 281 | 0.120 |
Why?
| | Postoperative Complications | 6 | 2014 | 2961 | 0.120 |
Why?
| | Immunity, Humoral | 1 | 2017 | 118 | 0.120 |
Why?
| | Preoperative Care | 2 | 2010 | 380 | 0.120 |
Why?
| | Liver Transplantation | 1 | 2003 | 826 | 0.120 |
Why?
| | Cholesterol, LDL | 3 | 2013 | 360 | 0.120 |
Why?
| | Trehalose | 1 | 2016 | 35 | 0.120 |
Why?
| | Neuropsychological Tests | 2 | 2018 | 1134 | 0.120 |
Why?
| | Bile Acids and Salts | 1 | 2017 | 163 | 0.120 |
Why?
| | Postoperative Period | 3 | 2011 | 351 | 0.120 |
Why?
| | Congenital Abnormalities | 1 | 2017 | 109 | 0.120 |
Why?
| | Health Services Accessibility | 3 | 2021 | 1099 | 0.120 |
Why?
| | Vascular Resistance | 2 | 2014 | 369 | 0.120 |
Why?
| | Lipogenesis | 1 | 2016 | 62 | 0.120 |
Why?
| | Heart Valve Diseases | 1 | 2017 | 151 | 0.110 |
Why?
| | Mutation | 3 | 2022 | 4071 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 486 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2017 | 273 | 0.110 |
Why?
| | Heart Rate | 2 | 2011 | 855 | 0.110 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2015 | 66 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 276 | 0.110 |
Why?
| | Risk Reduction Behavior | 2 | 2015 | 217 | 0.110 |
Why?
| | Phosphatidylethanolamines | 1 | 2015 | 76 | 0.110 |
Why?
| | Heart Arrest | 2 | 2016 | 408 | 0.110 |
Why?
| | Analysis of Variance | 3 | 2012 | 1300 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2017 | 166 | 0.110 |
Why?
| | Frail Elderly | 1 | 2016 | 136 | 0.110 |
Why?
| | Pregnancy | 3 | 2018 | 7182 | 0.110 |
Why?
| | Obstetric Labor, Premature | 1 | 2015 | 39 | 0.110 |
Why?
| | Risk | 5 | 2019 | 916 | 0.110 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2015 | 118 | 0.110 |
Why?
| | Global Health | 2 | 2015 | 403 | 0.110 |
Why?
| | Aorta, Abdominal | 2 | 2012 | 52 | 0.110 |
Why?
| | Maternal Mortality | 1 | 2015 | 53 | 0.110 |
Why?
| | Fibroblast Growth Factor 3 | 1 | 2014 | 3 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2013 | 2026 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 997 | 0.110 |
Why?
| | Metabolic Diseases | 2 | 2014 | 114 | 0.110 |
Why?
| | 24,25-Dihydroxyvitamin D 3 | 1 | 2014 | 2 | 0.110 |
Why?
| | Italy | 5 | 2014 | 114 | 0.100 |
Why?
| | Serine | 1 | 2015 | 143 | 0.100 |
Why?
| | Acetylcholine | 3 | 2023 | 208 | 0.100 |
Why?
| | Transcription Factor CHOP | 1 | 2014 | 32 | 0.100 |
Why?
| | Estrogen Replacement Therapy | 2 | 2014 | 143 | 0.100 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 474 | 0.100 |
Why?
| | Renal Artery | 1 | 2014 | 43 | 0.100 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 210 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2014 | 31 | 0.100 |
Why?
| | Organophosphonates | 1 | 2014 | 95 | 0.100 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 7 | 0.100 |
Why?
| | Endothelium | 1 | 2014 | 119 | 0.100 |
Why?
| | Infant, Small for Gestational Age | 1 | 2015 | 118 | 0.100 |
Why?
| | Steroid Hydroxylases | 1 | 2013 | 19 | 0.100 |
Why?
| | Tocopherols | 1 | 2013 | 31 | 0.100 |
Why?
| | Hand Strength | 2 | 2026 | 144 | 0.100 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2013 | 23 | 0.100 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.100 |
Why?
| | Qualitative Research | 4 | 2025 | 1671 | 0.100 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 133 | 0.100 |
Why?
| | Aortic Valve Stenosis | 2 | 2017 | 255 | 0.100 |
Why?
| | Statistics as Topic | 2 | 2017 | 283 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1505 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2026 | 5972 | 0.100 |
Why?
| | Glucose | 1 | 2018 | 1048 | 0.100 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 820 | 0.090 |
Why?
| | Premature Birth | 1 | 2017 | 387 | 0.090 |
Why?
| | Cesarean Section | 1 | 2015 | 229 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2013 | 76 | 0.090 |
Why?
| | Gastrointestinal Microbiome | 1 | 2020 | 766 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2019 | 731 | 0.090 |
Why?
| | Institutionalization | 1 | 2012 | 12 | 0.090 |
Why?
| | Ferric Compounds | 1 | 2012 | 54 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 917 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2017 | 562 | 0.090 |
Why?
| | Adenine | 1 | 2014 | 338 | 0.090 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2024 | 18 | 0.090 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 264 | 0.090 |
Why?
| | Causality | 2 | 2011 | 126 | 0.090 |
Why?
| | Cytokines | 2 | 2018 | 2048 | 0.090 |
Why?
| | Kynurenine | 2 | 2023 | 114 | 0.090 |
Why?
| | Tunica Media | 2 | 2010 | 37 | 0.090 |
Why?
| | Glycation End Products, Advanced | 1 | 2012 | 81 | 0.090 |
Why?
| | Aortic Aneurysm | 1 | 2012 | 70 | 0.090 |
Why?
| | Sympathetic Nervous System | 2 | 2015 | 181 | 0.090 |
Why?
| | Echocardiography, Stress | 2 | 2010 | 29 | 0.090 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 169 | 0.090 |
Why?
| | Postoperative Care | 2 | 2010 | 286 | 0.090 |
Why?
| | Chemokine CCL2 | 2 | 2024 | 112 | 0.090 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 291 | 0.090 |
Why?
| | Dietary Fiber | 1 | 2011 | 59 | 0.080 |
Why?
| | Hemostatic Disorders | 1 | 2011 | 1 | 0.080 |
Why?
| | Models, Biological | 3 | 2024 | 1763 | 0.080 |
Why?
| | International Classification of Diseases | 1 | 2012 | 149 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2014 | 1038 | 0.080 |
Why?
| | Cardiovascular System | 3 | 2020 | 138 | 0.080 |
Why?
| | Drug Combinations | 1 | 2012 | 396 | 0.080 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2662 | 0.080 |
Why?
| | Heart Failure, Systolic | 1 | 2010 | 26 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 53 | 0.080 |
Why?
| | Muscle Strength | 2 | 2023 | 332 | 0.080 |
Why?
| | Gout | 1 | 2010 | 34 | 0.080 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 109 | 0.080 |
Why?
| | Ticlopidine | 1 | 2010 | 52 | 0.080 |
Why?
| | Infant, Premature | 1 | 2015 | 619 | 0.080 |
Why?
| | Thinness | 1 | 2010 | 99 | 0.080 |
Why?
| | Alpha-Globulins | 2 | 2020 | 20 | 0.080 |
Why?
| | beta 2-Microglobulin | 2 | 2020 | 48 | 0.080 |
Why?
| | Aneurysm | 1 | 2009 | 37 | 0.080 |
Why?
| | Proteinuria | 2 | 2014 | 104 | 0.070 |
Why?
| | Nisoldipine | 1 | 2009 | 7 | 0.070 |
Why?
| | Enalapril | 1 | 2009 | 16 | 0.070 |
Why?
| | Genetic Loci | 1 | 2010 | 258 | 0.070 |
Why?
| | Arterial Occlusive Diseases | 1 | 2009 | 90 | 0.070 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 104 | 0.070 |
Why?
| | Radioisotope Renography | 1 | 2008 | 4 | 0.070 |
Why?
| | Regression Analysis | 3 | 2019 | 998 | 0.070 |
Why?
| | Texas | 1 | 2009 | 272 | 0.070 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2008 | 37 | 0.070 |
Why?
| | Tomography, Spiral Computed | 1 | 2008 | 30 | 0.070 |
Why?
| | Population Groups | 1 | 2009 | 56 | 0.070 |
Why?
| | Length of Stay | 1 | 2015 | 1348 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Chelating Agents | 2 | 2020 | 76 | 0.070 |
Why?
| | Delphi Technique | 2 | 2020 | 330 | 0.070 |
Why?
| | Databases as Topic | 1 | 2008 | 71 | 0.070 |
Why?
| | Perindopril | 1 | 2007 | 1 | 0.070 |
Why?
| | Demography | 1 | 2009 | 282 | 0.070 |
Why?
| | Osteogenesis | 2 | 2021 | 204 | 0.070 |
Why?
| | Diabetic Retinopathy | 1 | 2010 | 209 | 0.060 |
Why?
| | Endpoint Determination | 1 | 2008 | 85 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2014 | 920 | 0.060 |
Why?
| | Infant | 3 | 2018 | 10060 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 979 | 0.060 |
Why?
| | Aspirin | 1 | 2010 | 406 | 0.060 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 368 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2010 | 693 | 0.060 |
Why?
| | Mice, Knockout | 3 | 2023 | 3114 | 0.060 |
Why?
| | Estradiol | 1 | 2010 | 512 | 0.060 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2010 | 499 | 0.060 |
Why?
| | Testosterone | 1 | 2010 | 415 | 0.060 |
Why?
| | Forearm | 2 | 2017 | 141 | 0.060 |
Why?
| | Triglycerides | 3 | 2013 | 520 | 0.060 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2025 | 29 | 0.060 |
Why?
| | Protective Factors | 2 | 2016 | 99 | 0.060 |
Why?
| | Contrast Media | 1 | 2008 | 497 | 0.060 |
Why?
| | Calcifediol | 1 | 2024 | 31 | 0.050 |
Why?
| | Middle Cerebral Artery | 1 | 2025 | 56 | 0.050 |
Why?
| | Immunity, Innate | 1 | 2011 | 834 | 0.050 |
Why?
| | Vegetables | 1 | 2025 | 161 | 0.050 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 1188 | 0.050 |
Why?
| | Phagocytosis | 1 | 2006 | 296 | 0.050 |
Why?
| | Autoimmune Diseases | 1 | 2009 | 468 | 0.050 |
Why?
| | Outpatients | 1 | 2008 | 447 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1844 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 847 | 0.050 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2024 | 79 | 0.050 |
Why?
| | Nicotinamide Mononucleotide | 1 | 2023 | 9 | 0.050 |
Why?
| | Hemodialysis, Home | 1 | 2023 | 9 | 0.050 |
Why?
| | Respiratory Therapy | 1 | 2023 | 25 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| | Self-Help Groups | 1 | 2023 | 36 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2025 | 184 | 0.050 |
Why?
| | Cysts | 1 | 2024 | 112 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2003 | 126 | 0.050 |
Why?
| | Postmenopause | 1 | 2025 | 391 | 0.050 |
Why?
| | Kidney Glomerulus | 1 | 2003 | 125 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 56 | 0.050 |
Why?
| | Muscles | 1 | 2023 | 330 | 0.050 |
Why?
| | Least-Squares Analysis | 2 | 2012 | 73 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2207 | 0.040 |
Why?
| | NADPH Oxidases | 2 | 2013 | 122 | 0.040 |
Why?
| | Midazolam | 1 | 2022 | 73 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 862 | 0.040 |
Why?
| | Waist Circumference | 2 | 2012 | 143 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 227 | 0.040 |
Why?
| | Blood Flow Velocity | 1 | 2023 | 420 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 919 | 0.040 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 302 | 0.040 |
Why?
| | Activating Transcription Factor 4 | 1 | 2021 | 22 | 0.040 |
Why?
| | Vulnerable Populations | 1 | 2022 | 175 | 0.040 |
Why?
| | Endocannabinoids | 1 | 2022 | 56 | 0.040 |
Why?
| | Caregivers | 2 | 2020 | 1070 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 243 | 0.040 |
Why?
| | Social Isolation | 1 | 2021 | 73 | 0.040 |
Why?
| | Hematinics | 1 | 2020 | 22 | 0.040 |
Why?
| | Hepcidins | 1 | 2020 | 21 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3138 | 0.040 |
Why?
| | Clinical Trials as Topic | 2 | 2019 | 1058 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 238 | 0.040 |
Why?
| | Nephrologists | 1 | 2020 | 14 | 0.040 |
Why?
| | Administrative Personnel | 1 | 2020 | 33 | 0.040 |
Why?
| | Acute Disease | 2 | 2017 | 1035 | 0.040 |
Why?
| | Calcium Compounds | 1 | 2020 | 5 | 0.040 |
Why?
| | Asia | 1 | 2020 | 70 | 0.040 |
Why?
| | Biopsy | 1 | 2003 | 1079 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1264 | 0.040 |
Why?
| | Serum Albumin | 1 | 2020 | 146 | 0.040 |
Why?
| | Vitamin B Complex | 1 | 2020 | 39 | 0.040 |
Why?
| | Africa | 1 | 2020 | 118 | 0.040 |
Why?
| | California | 2 | 2012 | 471 | 0.040 |
Why?
| | Hypoglycemic Agents | 2 | 2024 | 1393 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2020 | 83 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2021 | 213 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4552 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 37 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 404 | 0.040 |
Why?
| | Models, Animal | 1 | 2021 | 393 | 0.040 |
Why?
| | Intracranial Aneurysm | 1 | 2020 | 106 | 0.040 |
Why?
| | HIV Infections | 1 | 2014 | 3186 | 0.040 |
Why?
| | Health Literacy | 1 | 2021 | 184 | 0.040 |
Why?
| | Social Stigma | 1 | 2021 | 172 | 0.040 |
Why?
| | Glucuronidase | 1 | 2018 | 27 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 664 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 571 | 0.030 |
Why?
| | Patients | 1 | 2020 | 183 | 0.030 |
Why?
| | Symptom Flare Up | 1 | 2018 | 37 | 0.030 |
Why?
| | Sodium Chloride Symporter Inhibitors | 1 | 2018 | 8 | 0.030 |
Why?
| | Aftercare | 1 | 2020 | 222 | 0.030 |
Why?
| | Urban Population | 1 | 2021 | 492 | 0.030 |
Why?
| | Career Choice | 1 | 2020 | 234 | 0.030 |
Why?
| | Self Concept | 1 | 2020 | 253 | 0.030 |
Why?
| | Publications | 1 | 2018 | 47 | 0.030 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 31 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 478 | 0.030 |
Why?
| | Registries | 2 | 2021 | 2401 | 0.030 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2019 | 166 | 0.030 |
Why?
| | Fathers | 1 | 2018 | 53 | 0.030 |
Why?
| | Fibrosis | 1 | 2020 | 554 | 0.030 |
Why?
| | NF-kappa B | 2 | 2012 | 664 | 0.030 |
Why?
| | Intelligence Tests | 1 | 2017 | 55 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2018 | 219 | 0.030 |
Why?
| | Mitral Valve Stenosis | 1 | 2017 | 20 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2021 | 399 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 234 | 0.030 |
Why?
| | Cholesterol | 1 | 2019 | 406 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2018 | 166 | 0.030 |
Why?
| | Femur Neck | 1 | 2017 | 62 | 0.030 |
Why?
| | Energy Intake | 1 | 2020 | 507 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 439 | 0.030 |
Why?
| | Safety-net Providers | 1 | 2018 | 129 | 0.030 |
Why?
| | Diuretics | 1 | 2016 | 68 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2021 | 692 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 198 | 0.030 |
Why?
| | Methemoglobin | 1 | 2015 | 24 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 173 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2010 | 1995 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 497 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 946 | 0.030 |
Why?
| | Program Development | 1 | 2018 | 368 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2026 | 1789 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 450 | 0.030 |
Why?
| | Anthropometry | 1 | 2016 | 205 | 0.030 |
Why?
| | White Matter | 1 | 2017 | 152 | 0.030 |
Why?
| | Research | 1 | 2018 | 430 | 0.030 |
Why?
| | Elasticity | 1 | 2015 | 189 | 0.030 |
Why?
| | Renal Elimination | 1 | 2014 | 5 | 0.030 |
Why?
| | Renal Reabsorption | 1 | 2014 | 4 | 0.030 |
Why?
| | Gastrointestinal Absorption | 1 | 2014 | 5 | 0.030 |
Why?
| | Urinalysis | 1 | 2015 | 83 | 0.030 |
Why?
| | Vasodilator Agents | 1 | 2017 | 330 | 0.030 |
Why?
| | Prenatal Diagnosis | 1 | 2016 | 196 | 0.030 |
Why?
| | Ketocholesterols | 1 | 2014 | 8 | 0.030 |
Why?
| | France | 1 | 2014 | 40 | 0.030 |
Why?
| | Age of Onset | 1 | 2016 | 554 | 0.030 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2014 | 40 | 0.030 |
Why?
| | Research Design | 2 | 2011 | 1132 | 0.030 |
Why?
| | Ezetimibe | 1 | 2014 | 24 | 0.030 |
Why?
| | Prostaglandins | 1 | 2014 | 94 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2019 | 708 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 61 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 237 | 0.030 |
Why?
| | Actigraphy | 1 | 2015 | 147 | 0.030 |
Why?
| | Azetidines | 1 | 2014 | 45 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2018 | 907 | 0.030 |
Why?
| | F2-Isoprostanes | 1 | 2013 | 20 | 0.030 |
Why?
| | Societies, Medical | 1 | 2018 | 898 | 0.030 |
Why?
| | Apolipoproteins E | 1 | 2014 | 93 | 0.030 |
Why?
| | Aortic Valve | 1 | 2017 | 364 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 17 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2014 | 62 | 0.030 |
Why?
| | Needs Assessment | 1 | 2017 | 401 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 20 | 0.030 |
Why?
| | Erythropoiesis | 1 | 2013 | 57 | 0.030 |
Why?
| | Acute Coronary Syndrome | 1 | 2017 | 297 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2021 | 4142 | 0.020 |
Why?
| | Pulse | 1 | 2013 | 29 | 0.020 |
Why?
| | Immunotherapy | 1 | 2018 | 665 | 0.020 |
Why?
| | Program Evaluation | 1 | 2018 | 943 | 0.020 |
Why?
| | Health Personnel | 1 | 2020 | 749 | 0.020 |
Why?
| | Immunoblotting | 1 | 2013 | 295 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2018 | 2185 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2351 | 0.020 |
Why?
| | Executive Function | 1 | 2018 | 469 | 0.020 |
Why?
| | Signal Transduction | 2 | 2018 | 5208 | 0.020 |
Why?
| | Cell Line | 1 | 2018 | 2821 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 119 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2013 | 365 | 0.020 |
Why?
| | Random Allocation | 1 | 2013 | 365 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 781 | 0.020 |
Why?
| | Tenofovir | 1 | 2014 | 300 | 0.020 |
Why?
| | Xanthine Oxidase | 1 | 2012 | 79 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2012 | 85 | 0.020 |
Why?
| | Biological Availability | 1 | 2012 | 144 | 0.020 |
Why?
| | Germany | 1 | 2012 | 137 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2018 | 1127 | 0.020 |
Why?
| | Microcirculation | 1 | 2012 | 142 | 0.020 |
Why?
| | Blood Glucose | 2 | 2012 | 2335 | 0.020 |
Why?
| | Ventricular Remodeling | 1 | 2014 | 277 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2013 | 1048 | 0.020 |
Why?
| | Mothers | 1 | 2018 | 764 | 0.020 |
Why?
| | Insulin | 2 | 2013 | 2510 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2020 | 1145 | 0.020 |
Why?
| | Metoprolol | 1 | 2011 | 26 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2012 | 119 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 70 | 0.020 |
Why?
| | Nitroglycerin | 1 | 2010 | 14 | 0.020 |
Why?
| | Salicylates | 1 | 2010 | 29 | 0.020 |
Why?
| | Aortic Diseases | 1 | 2012 | 125 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 367 | 0.020 |
Why?
| | Arteries | 1 | 2012 | 261 | 0.020 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.020 |
Why?
| | Stroke Volume | 1 | 2013 | 653 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 428 | 0.020 |
Why?
| | Sunlight | 1 | 2010 | 77 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2012 | 307 | 0.020 |
Why?
| | Area Under Curve | 1 | 2010 | 329 | 0.020 |
Why?
| | Life Style | 1 | 2012 | 483 | 0.020 |
Why?
| | Lipids | 1 | 2014 | 706 | 0.020 |
Why?
| | Thyroid Function Tests | 1 | 2009 | 19 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 647 | 0.020 |
Why?
| | Cystatins | 1 | 2008 | 7 | 0.020 |
Why?
| | Elective Surgical Procedures | 1 | 2010 | 202 | 0.020 |
Why?
| | Myocardial Ischemia | 1 | 2010 | 285 | 0.020 |
Why?
| | ROC Curve | 1 | 2010 | 617 | 0.020 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2008 | 30 | 0.020 |
Why?
| | Dobutamine | 1 | 2007 | 24 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2524 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 322 | 0.020 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2008 | 156 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1320 | 0.020 |
Why?
| | Hemodynamics | 1 | 2011 | 1115 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2377 | 0.010 |
Why?
| | Exercise | 1 | 2018 | 2191 | 0.010 |
Why?
| | Perioperative Care | 1 | 2008 | 231 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2013 | 1188 | 0.010 |
Why?
| | Rats | 1 | 2013 | 5582 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 2007 | 539 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1376 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6055 | 0.010 |
Why?
|
|
Chonchol's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|